Don Newling

2.0k total citations
56 papers, 1.4k citations indexed

About

Don Newling is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Don Newling has authored 56 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 20 papers in Surgery and 11 papers in Oncology. Recurrent topics in Don Newling's work include Prostate Cancer Treatment and Research (28 papers), Prostate Cancer Diagnosis and Treatment (24 papers) and Bladder and Urothelial Cancer Treatments (13 papers). Don Newling is often cited by papers focused on Prostate Cancer Treatment and Research (28 papers), Prostate Cancer Diagnosis and Treatment (24 papers) and Bladder and Urothelial Cancer Treatments (13 papers). Don Newling collaborates with scholars based in Netherlands, United Kingdom and United States. Don Newling's co-authors include Simon Horenblas, Louis Denis, Peter A. Humphrey, Thomas M. Wheeler, Rodolfo Montironi, Mahul B. Amin, Sten Nilsson, Lars Egevad, Jonathan I. Epstein and Liliane Boccon‐Gibod and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Annals of Oncology.

In The Last Decade

Don Newling

56 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Don Newling Netherlands 21 727 470 292 261 261 56 1.4k
Joseph W. Basler United States 23 1.1k 1.5× 362 0.8× 355 1.2× 250 1.0× 314 1.2× 63 2.0k
M. Shelley United Kingdom 19 503 0.7× 882 1.9× 364 1.2× 198 0.8× 141 0.5× 34 1.8k
M. R. G. Robinson United Kingdom 23 841 1.2× 547 1.2× 308 1.1× 184 0.7× 120 0.5× 60 1.6k
Libni Eapen Canada 24 809 1.1× 703 1.5× 384 1.3× 149 0.6× 60 0.2× 72 1.8k
Marco Oderda Italy 24 760 1.0× 706 1.5× 203 0.7× 365 1.4× 254 1.0× 133 1.8k
Rabi Tiguert United States 26 1.1k 1.5× 703 1.5× 268 0.9× 300 1.1× 385 1.5× 77 1.8k
Zev Wajsman United States 25 1.3k 1.8× 1.2k 2.5× 324 1.1× 460 1.8× 400 1.5× 83 2.5k
Joseph R. Drago United States 23 994 1.4× 737 1.6× 227 0.8× 354 1.4× 331 1.3× 104 2.0k
Fouad Aoun Belgium 18 690 0.9× 297 0.6× 204 0.7× 218 0.8× 239 0.9× 99 1.2k
Bjørn Brennhovd Norway 14 391 0.5× 411 0.9× 108 0.4× 125 0.5× 114 0.4× 39 873

Countries citing papers authored by Don Newling

Since Specialization
Citations

This map shows the geographic impact of Don Newling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Don Newling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Don Newling more than expected).

Fields of papers citing papers by Don Newling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Don Newling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Don Newling. The network helps show where Don Newling may publish in the future.

Co-authorship network of co-authors of Don Newling

This figure shows the co-authorship network connecting the top 25 collaborators of Don Newling. A scholar is included among the top collaborators of Don Newling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Don Newling. Don Newling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bosschieter, Judith, Jakko A. Nieuwenhuijzen, André N. Vis, et al.. (2017). Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non–muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients. European Urology. 73(2). 226–232. 79 indexed citations
2.
McCabe, Christopher, Lothar Bergmann, Nicholas Bosanquet, et al.. (2008). Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Annals of Oncology. 20(3). 403–412. 52 indexed citations
3.
Penson, David F., Judd W. Moul, Sanjay Gandhi, & Don Newling. (2006). Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: Results of a nationwide survey of urologists. Urology. 68(1). 80–84. 2 indexed citations
4.
Kane, Richard D., Kathleen M. Fox, Sanjay Gandhi, et al.. (2005). Relative importance of PSA in prostate cancer treatment. Urologic Oncology Seminars and Original Investigations. 23(4). 238–245. 1 indexed citations
5.
Haarst, Ernst P. van, et al.. (2004). A Cross-Sectional Study of the International Prostate Symptom Scores Related to Age and Gender in Dutch Adults Reporting No Voiding Complaints. European Urology. 47(3). 334–339. 8 indexed citations
6.
Haarst, Ernst P. van, et al.. (2004). The 24‐h frequency‐volume chart in adults reporting no voiding complaints: defining reference values and analysing variables. British Journal of Urology. 93(9). 1257–1261. 74 indexed citations
7.
Newling, Don. (2003). Immediate or Deferred Hormonal Therapy?. Scandinavian Journal of Urology and Nephrology. 37(0). 16–19. 2 indexed citations
8.
Geldof, Albert A., et al.. (2003). Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line. Journal of Cancer Research and Clinical Oncology. 129(3). 175–182. 28 indexed citations
9.
Newling, Don, et al.. (2002). PROTOTHECOSIS OF THE URINARY TRACT. The Journal of Urology. 252–252. 1 indexed citations
10.
Poppel, Hendrik Van, et al.. (2001). Quality control of radical prostatectomy. European Journal of Cancer. 37(7). 884–891. 20 indexed citations
11.
Horenblas, Simon, et al.. (2000). Use of Balloon Catheters for Ureteral Occlusion in Urinary Leakage. European Urology. 38(5). 613–617. 12 indexed citations
12.
Simoons‐Smit, A. M., Paul H. M. Savelkoul, Don Newling, & Christina M. J. E. Vandenbroucke‐Grauls. (2000). Chronic Cystitis Caused by Corynebacterium urealyticum Detected by Polymerase Chain Reaction. European Journal of Clinical Microbiology & Infectious Diseases. 19(12). 949–952. 17 indexed citations
13.
Fitzpatrick, J. M., et al.. (1998). Sexual Dysfunction Associated with the Management of Prostate Cancer. European Urology. 33(6). 513–522. 11 indexed citations
14.
Newling, Don. (1997). Second-line treatment of metastatic prostatic carcinoma. Urological Research. 25(S2). S73–S78. 10 indexed citations
15.
Newling, Don, et al.. (1995). Tryptophan Metabolites,Pyridoxine (Vitamin B(6)) and TheirInfluence on the Recurrence Rateof Superficial Bladder Cancer. European Urology. 27(2). 110–116. 52 indexed citations
16.
Horenblas, Simon, Robert Kröger, M.P.W. Gallee, Don Newling, & Harm van Tinteren. (1994). Ultrasound in squamous cell carcinoma of the penis; A useful addition to clinical staging? A comparison of ultrasound with histopathology. Urology. 43(5). 702–707. 38 indexed citations
17.
Newling, Don. (1992). What is “progression” in prostate cancer?. The Prostate. 21(S4). 139–143. 4 indexed citations
18.
Fosså, Sophie D., Elisabeth Paus, Mette Winderen Lindegaard, & Don Newling. (1992). Prostate‐specific Antigen and other Prognostic Factors in Patients with Hormone‐resistant Prostatic Cancer Undergoing Experimental Treatment. British Journal of Urology. 69(2). 175–179. 30 indexed citations
19.
Fosså, Sophie D., et al.. (1990). Quality of life and treatment of hormone resistant metastatic prostatic cancer. European Journal of Cancer and Clinical Oncology. 26(11-12). 1133–1136. 122 indexed citations
20.
Fosså, Sophie D., et al.. (1989). Quality of Life in Patients with Muscle-Infiltrating Bladder Cancerand Hormone-Resistant Prostatic Cancer. European Urology. 16(5). 335–339. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joseph W. Basler Breakdown of academic impact, for papers by M. Shelley Breakdown of academic impact, for papers by M. R. G. Robinson Breakdown of academic impact, for papers by Libni Eapen Breakdown of academic impact, for papers by Marco Oderda Breakdown of academic impact, for papers by Rabi Tiguert Breakdown of academic impact, for papers by Zev Wajsman Breakdown of academic impact, for papers by Joseph R. Drago Breakdown of academic impact, for papers by Fouad Aoun Breakdown of academic impact, for papers by Bjørn Brennhovd
Rankless by CCL
2026